Avalo Therapeutics (AVTX) Deferred Taxes (2017 - 2026)
Avalo Therapeutics (AVTX) posted Deferred Taxes of $12000.0 for Q1 2026, down 90.84% on a QoQ basis from $131000.0 in Q4 2025, and up 50.0% year-over-year from $8000.0 in Q1 2025.
Avalo Therapeutics (AVTX) Deferred Taxes (2017 - 2026) Analysis & Trends
Avalo Therapeutics' Deferred Taxes history runs 10 years deep, the most recent figure standing at $12000.0 for Q1 2026.
- Quarterly Deferred Taxes rose 50.0% year-over-year to $12000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $169000.0 (up 46.96% YoY) and the FY2025 annual result came in at $165000.0, up 44.74% from the prior year.
- Deferred Taxes was $12000.0 for Q1 2026 at Avalo Therapeutics, down from $131000.0 in the prior quarter.
- Across five years, Deferred Taxes topped out at $131000.0 in Q4 2025 and bottomed at -$14000.0 in Q3 2024.
- A 5-year average of $19588.2 and a median of $8000.0 in 2022 frame the typical range for Deferred Taxes.
- Peak annual rise in Deferred Taxes reached 1366.67% in 2024, while the deepest fall reached 275.0% in 2024.
- Avalo Therapeutics' Deferred Taxes stood at $8000.0 in 2022, then sank by 212.5% to -$9000.0 in 2023, then surged by 1366.67% to $114000.0 in 2024, then advanced by 14.91% to $131000.0 in 2025, then sank by 90.84% to $12000.0 in 2026.
- Business Quant data shows AVTX's Deferred Taxes at $12000.0 in Q1 2026, $131000.0 in Q4 2025, and $10000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -188,883.60 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -65.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 96.00 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Avalo Therapeutics | 1.04 Mn | 1.04 Mn | - | 12,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12,000.00 |
| Dec 31, 2025 | 131,000.00 |
| Sep 30, 2025 | 10,000.00 |
| Jun 30, 2025 | 16,000.00 |
| Mar 31, 2025 | 8,000.00 |
| Dec 31, 2024 | 114,000.00 |
| Sep 30, 2024 | -14,000.00 |
| Jun 30, 2024 | 7,000.00 |
| Mar 31, 2024 | 7,000.00 |
| Dec 31, 2023 | -9,000.00 |
| Sep 30, 2023 | 8,000.00 |
| Jun 30, 2023 | 7,000.00 |
| Mar 31, 2023 | 8,000.00 |
| Dec 31, 2022 | 8,000.00 |
| Sep 30, 2022 | 5,000.00 |
| Jun 30, 2022 | 6,000.00 |
| Mar 31, 2022 | 9,000.00 |
| Dec 31, 2021 | -62,000.00 |
| Sep 30, 2021 | 9,000.00 |
| Jun 30, 2021 | 10,000.00 |